Pediatric Drugs Market Report 2026

Pediatric Drugs Market Overview

• Pediatric Drugs market size has reached to $179.43 billion in 2025 • Expected to grow to $352.69 billion in 2030 at a compound annual growth rate (CAGR) of 14.4% • Growth Driver: Impact Of Growing Preterm Births On The Market Growth • Market Trend: Pharma Companies Launch Long Acting Monoclonal Antibodies to Protect Infants Against RSV • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Pediatric Drugs Market?

Pediatric drugs are medications specifically formulated, dosed, or approved for use in infants, children, and adolescents. These drugs are designed to treat various medical conditions in pediatric patients, considering their unique physiological and metabolic differences from adults. The main types of drugs in the pediatric drugs are respiratory disorder drugs, autoimmune disorder drugs, gastrointestinal drugs, and cardiovascular drugs. Respiratory disorder drugs are medications designed to treat breathing-related conditions in children, such as asthma, cystic fibrosis, and RSV. These drugs are administered through various routes, such as oral, topical, parenteral, and other methods, and distributed through different channels, including hospital pharmacies, retail pharmacies, online pharmacies, and other distribution channels. They are used by various end-users, including hospitals, specialty clinics, homecare, and other healthcare settings.

What Is The Pediatric Drugs Market Growth Forecast?

The pediatric drugs market size is expected to see rapid growth in the next few years. It will grow to $352.69 billion in 2030 at a compound annual growth rate (CAGR) of 14.4%. The growth in the forecast period can be attributed to rising pediatric population in emerging markets, growth in childhood chronic conditions, increasing investment in pediatric drug research, expansion of child-focused healthcare policies, rising demand for safer pediatric therapies. Major trends in the forecast period include increasing demand for age-appropriate drug formulations, growing focus on pediatric-specific dosage accuracy, rising use of liquid and chewable pediatric medicines, expansion of pediatric chronic disease management, increased regulatory emphasis on pediatric clinical trials.

Global Pediatric Drugs Market Segmentation

1) By Type: Respiratory Disorder Drugs, Autoimmune Disorder Drugs, Gastrointestinal Drugs, Cardiovascular Drugs 2) By Route Of Administration: Oral, Topical, Parenteral, Other Route Of Administrations 3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels 4) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End-Users Subsegments: 1) By Respiratory Disorder Drugs: Asthma Medications, Cystic Fibrosis Treatments, Bronchodilators, Corticosteroids 2) By Autoimmune Disorder Drugs: Immunosuppressants, Biologic Therapies, Disease-Modifying Antirheumatic Drugs (DMARDs) 3) By Gastrointestinal Drugs: Proton Pump Inhibitors (PPIs), Antiemetics, Antidiarrheals, Laxatives 4) By Cardiovascular Drugs: Antihypertensive Medications, Heart Failure Treatments, Antiarrhythmic Drugs, Lipid-lowering Agents

What Is The Driver Of The Pediatric Drugs Market?

The growing number of preterm births is expected to propel the growth of the pediatric drugs market going forward. Preterm births refer to babies born before 37 weeks of pregnancy, which is earlier than the typical 40-week gestation period. The growing number of preterm births is attributed to factors such as increased maternal age, lifestyle choices, medical conditions, multiple pregnancies, and inadequate prenatal care. Pediatric drugs are essential in aiding the health and development of preterm infants by offering targeted treatments for challenges such as respiratory problems, infections, and nutritional gaps. For instance, in 2023, according to Tommy’s, a UK-based charity organization, the percentage of premature live births in England and Wales rose to 8.1%, up from 7.9% in 2022 corresponding to more than 48,000 babies born prematurely in that year. Therefore, the growing number of preterm births are driving the growth of the pediatric drugs industry.

Key Players In The Global Pediatric Drugs Market

Major companies operating in the pediatric drugs market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb, AstraZeneca Plc, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company, Eli Lilly and Co., Gilead Sciences Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Vertex Pharmaceuticals, UCB Pharma, Sun Pharmaceutical Industries Ltd., Perrigo Company, Shionogi & Co. Ltd., Mallinckrodt, Torrent Pharmaceuticals Ltd, Sarepta Therapeutics, Zydus Cadila

Global Pediatric Drugs Market Trends and Insights

Major companies operating in the pediatric drugs market are increasingly launching long acting monoclonal antibodies for infectious diseases in infants, such as extended half life RSV prevention therapies. A long acting monoclonal antibody is a biologic designed to remain in the bloodstream for an extended duration, thereby providing sustained protection with fewer doses. For instance, in June 2025, Merck, a US-based pharmaceutical company, received FDA approval for clesrovimab (Enflonsia), a fully human mAb that prevents respiratory syncytial virus (RSV) in infants. Clesrovimab features extended half-life through enhanced Fc receptor binding, offers durable protection across the first RSV season, and can be administered in a single intramuscular dose.

What Are Latest Mergers And Acquisitions In The Pediatric Drugs Market?

In January 2023, Ipsen, a France-based biopharmaceutical company, acquired Albireo Pharma for approximately US$ 952 million. With this acquisition, Ipsen aims to expand its presence in the pediatric segment, leveraging Albireo’s lead product, odevixibat (Bylvay), which treats progressive familial intrahepatic cholestasis (PFIC), to strengthen its rare-disease portfolio and support future growth in pediatric therapeutics. Albireo Pharma is a US-based biopharmaceutical company specializing in developing treatments for rare pediatric liver diseases.

Regional Insights

North America was the largest region in the pediatric drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Pediatric Drugs Market?

The pediatric drugs market consists of sales of antibiotics, vaccines, pediatric pain relief, respiratory medications, antihistamines, and pediatric dermatology products. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Pediatric Drugs Market Report 2026?

The pediatric drugs market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the pediatric drugs industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.